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Abstract
Nocturnal polyuria (NP) is an important cause of nocturia and it is related to an imbalance in water and/or sodium
homeostasis. Antidiuretic hormone (ADH) and atrial natriuretic peptide (ANP) are believed to play an important role
in this excessive urine production overnight, however, many other hormones are involved. ADH and ANP are both
directly and indirectly influenced by the renin-angiotensin-aldosterone system (RAAS), prostaglandins antagonize
both ADH and RAAS and sex hormones have a predominantly antidiuretic effect by stimulating ADH and RAAS,
meaning that any disturbance can lead to an imbalance in diuresis. Since nocturia is a condition affecting sleep,
melatonin secretion can also be affected, leading to a decrease in the antidiuretic effect and to an increase of
nocturnal urine production. Depending on the underlying condition affecting any of these hormones, a more specific
therapeutic approach might lead to a restoration of the normal diuresis cycle and to a good night’s sleep. The
characteristics of each of these hormones, the pathophysiology in NP and the therapeutic implications are set out in
this review.
Keywords: Nocturnal polyuria; Antidiuretic hormone; Renin-
angiotensin-aldosterone; Atrial natriuretic peptide; Pathophysiology;
Therapeutic implications
Introduction
Nocturia is the need to get up once or more to void at night. The
underlying problem can be reduced bladder capacity, diurnal polyuria
and nocturnal polyuria; each of these can be caused by several
conditions. In this review we would focus on the problem of nocturnal
polyuria [1].
To fully understand this topic, a basic knowledge of water and
sodium homeostasis is necessary. Nocturnal polyuria due to
disturbances in water handling is usually caused by an impairment of
the antidiuretic hormone. If a disturbance in sodium handling seems
to be the problem, natriuretic peptides are often involved [2,3]. Both of
these hormones affect and are affected by the renin-angiotensin-
aldosterone system [4]. But there is also evidence that other hormones,
such as melatonin and sex hormones affect these pathways one way or
another [5,6].Therefore this article highlights the physiological
mechanisms of each of these hormones and discusses how this fits in
the pathophysiology of nocturnal polyuria, providing evidence for
pharmacotherapeutic options.
Antidiuretic Hormone
Characteristics
ADH is the predominant hormone that regulates the rate of free
water excretion. It is a neurohypophyseal polypeptide that is
synthesized in the supraoptic and paraventricular nuclei and is
secreted after migration to the posterior lobe of the pituitary as a
response to the appropriate stimuli [7]. ADH secretion is mainly
influenced by the input from the osmotic and volume receptors, with
an increase due to hyperosmolality and volume depletion, respectively.
But multiple other stimuli play a role such as stress situations, nausea
and hypoglycemia. Nicotine and morphine also enhance ADH release
[8,9].
There are three receptors for ADH, by binding to the V1 receptor
vasoconstriction and prostaglandin release occurs; stimulation of the
V1b or V3 receptor facilitates the release of adrenocorticotropic
hormone (ACTH) in the pituitary. Activation of the V2 receptor
mediates the antidiuretic response by fusing the ADH-sensitive water
channels, aquaporin-2, with the luminal membrane of the collecting
tubules in the nephrons. This process allows water to be reabsorbed
down the osmotic gradient towards the systemic circulation across the
basolateral membrane. Once the ADH effect has worn off, the water
channels return to the cytoplasm after endocytosis [10].
ADH also appears to affect electrolyte handling by enhancing
sodium reabsorption and secretion of potassium in the cortical
collecting tubule; however, these effects do not seem to be of major
importance in maintaining the electrolyte balance [11,12].
NP pathophysiology
In older people with nocturnal polyuria a decrease in nocturnal
ADH secretion seems to be an important factor. Moon et al. and
Asplund found this impaired circadian rhythm of plasma ADH levels
during night time in small study samples (12 and 23 subjects,
respectively) with a mean age of 68 and 71 years old, respectively
[13,14].
And although a loss of circadian rhythm of ADH is believed to be a
normal aging process, the contribution of an impairment of this
hormone is reinforced by the evidence that low nocturnal ADH levels
are also found in children with nocturnal enuresis based on nocturnal
polyuria [15].
Studies in which the urinary ADH levels were measured show
conflicting evidence, Hirayama et al. found a decrease in urinary ADH
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excretion early in the morning in patients with NP, while Akiyama et
al. showed that more than 30% of the older people (>50 years old,
mean age 75) with NP present with increased urinary ADH excretion
rates. The latter implies that not only an impaired secretion may cause
NP, but also an impaired response to ADH, which can be caused for
example by drugs and electrolyte abnormalities [16,17].
Therapeutical implications
Desmopressin is a synthetic analogue of ADH and is currently the
only drug approved for treatment of nocturia due to nocturnal
polyuria. Compared to the endogenous ADH, desmopressin has a
pronounced antidiuretic effect and little to no vasopressor effect [18].
 
Desmopressin has proven to lower nocturnal urine production and to
prolong the initial sleep period, thus improving the sleep quality of the
patients. Beneficial effects both on short-term and long-term have
been confirmed [19,20]. Adverse effects are limited; however, a risk for
potentially fatal hyponatriemia has to be taken in account, definitely in
an older population and in women who seem to be more prone to this
adverse effect [21].
 
Renin-Angiotensin-Aldosterone System
Characteristics
The renin-angiotensin-aldosterone system is of major importance
in maintaining blood pressure and fluid volume. It exerts this function
through regulation of renal blood flow and solute reabsorption,
thereby affecting the urine production [4].
Renin: The activity of these systems depends on the level of renin
gene expression and on conversion of prorenin to active renin by
proteolytic removal of a 43 amino acid prosegment. Renin is stored in
secretory granules of the juxtaglomerular cells of the kidney and is
released in response to various physiological stimuli, such as low blood
pressure blockade of Ang II production or decreases in distal tubular
sodium. It is an enzyme that triggers the cascade by cleaving the liver-
derived angiotensinogen into angiotensin I (Ang I) [22,23].
 
The major determinant of renin secretion is sodium intake; low intake
or fluid loss lowers the extracellular volume and stimulates renin
secretion [24]. There are three mechanisms regulating renin release.
The first is through afferent arteriolar baroreceptors; in response to
low arterial perfusion pressure renin release increases. The second is
through sympathetic innervation of the juxtaglomerular cells,
stimulation of these neurons leads to norepinephrine release and
subsequent stimulation of beta1-adrenergic receptors stimulating
renin release. The third is a negative feedback mechanism through
binding of Ang II to AT1 and AT2 receptors [25,26].
Angiotensin: Within the lungs, the inactive Ang I is converted by
the angiotensin-converting enzyme (ACE) into the active angiotensin
II. The effect of Ang II depends on the type of receptor that is
stimulated. Binding of AngII to the AT1-receptor results in a variation
of effects on vasculature, heart and kidney, such as vasoconstriction,
increase of cardiac contractility and aldosterone and ADH secretion.
Sodium reabsorption is not only stimulated indirectly through
aldosterone, but also directly through stimulation of sodium transport
in the early proximal tubule [22,23].
Stimulation of AT2-receptors results in the opposite effect with
vasodilation and natriuresis, however, since these receptors are highly
expressed in fetal tissues but then substantially regress, they are
believed to be of minor importance in adults [27].
Aldosterone: Aldosterone is a mineralocorticoid hormone that is
synthesized and secreted by the adrenals in response to Ang II and
potassium. It stimulates mineralocorticoid receptors in the distal
nephron leading to sodium reabsorption through epithelial sodium
channels. The accompanying water retention expands blood and
extracellular fluid volumes [28].
 
In situations of aldosterone overproduction, such as in primary
hyperaldosteronism, an ‘aldosterone escape’ is seen, where the initial
sodium retention is counteracted by increased ANP levels and an
elevation in systemic blood pressure leading to natriuresis after 1 to 2
days in order to restore plasma volume towards normal [29].
NP pathophysiology
In children with nocturnal enuresis based on nocturnal polyuria a
lack of circadian rhythm in plasma angiotensin II levels is found,
which correlates with an attenuated rhythm in mean blood pressure
[30]. And although evidence is limited, it has also been described that
nocturnal angiotensin II levels are lower in adults with NP, together
with a decrease in ADH [31]. Besides, a link between a non-dipping
pattern in mean arterial blood pressure and nocturia in adults is
found, pleading for the same underlying pathophysiologic
mechanisms as found in children with nocturnal polyuria [32]. This
non-dipping pattern is characterized by diminished renal sodium
excretory capability, low plasma renin activity and normal aldosterone
levels. The relative aldosterone excess with sodium retention during
daytime leads to enhanced sodium excretion during night time [33]. In
arterial hypertension higher levels of blood pressure are required to
excrete the same amount of sodium, which is called pressure-
natriuresis [32]. This pressure natriuresis is accomplished by increased
glomerular capillary pressure, as seen in deteriorated renal function
and increasing age [34].
 
The non-dipping pattern is also found in subjects with sodium
sensitive hypertension, in whom a significant rise in blood pressure
occurs as a response to sodium loading. Many factors seem to play a
role in this type of hypertension, salt sensitivity is related to older age,
female sex, and is possibly genetically determined. Lower renin and
aldosterone levels are found in these subjects, together with a
decreased number of beta2-receptors. Atrial natriuretic peptide also
seems to play a role, although there is no consensus on lower levels of
ANP or a lower response to ANP [35].
Therapeutical implications
In subjects with sodium sensitive hypertension a reduction in
sodium intake has been proven to be effective in lowering nocturnal
blood pressure and thus affecting the nocturnal sodium excretion. In
high sodium load the defect in sodium excretory capability becomes
more evident, leading to the above mentioned mechanisms and thus
nocturnal polyuria. Sodium restriction is considered one of the most
important lifestyle measures to address hypertension and renal
diseases and can indirectly affect nocturnal urine production [36].
Angiotensin II type 1 receptor blockers administered in the
morning seem to restore the circadian rhythms of blood pressure and
natriuresis from nocturnal non-dipping to dipping patterns in patients
with chronic kidney disease. This is, however, not only due to
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inhibition of the RAS itself, but mainly through enhanced renal
sodium excretion during daytime [37]. This is similar to the effect of
diuretics on nocturnal polyuria as described below [38].
 
Natriuretic peptide
Characteristics
Atrial natriuretic peptide: Atrial natriuretic peptide (ANP) is the
main natriuretic hormone; it is a 28-amino-acid polypeptide that is
released from myocardial cells in the atria and in some cases the
ventricles. ANP stimulates natriuretic peptide receptors (NPR) in the
glomeruli and inner medullary collecting ducts [39].
This peptide functions as a direct vasodilator and also increases
urinary sodium and water excretion. The latter effect is mediated by
various renal and extra renal changes. The natriuretic action is
primarily caused by inhibition of sodium reabsorption in the
medullary collecting tubule. There still is controversy about the same
effect on the proximal tubule, but in case of high ANP levels
glomerular filtration rate is increased, which also leads to natriuresis
[40].
But there are other pathways through which ANP exercises its
natriuretic and diuretic effects, such as through the effect on the renin-
angiotensin-aldosterone system. In the proximal tubule, ANP inhibits
the angiotensin-mediated sodium and fluid reabsorption. Besides that,
ANP antagonizes the actions of aldosterone and of ADH [41,42].
Brain natriuretic peptide: Brain natriuretic peptide (BNP) is
homologous to ANP and is present in both the brain and the heart.
Circulating concentration of BNP is less than 20% of that of ANP, but
in congestive heart failure patients it can easily exceed these rates [43].
The physiologic role of BNP remains to be determined, but it
definitely plays a role in volume status. In ten male volunteers volume
loading with an infusion of 15 ml/kg of 0.9% NaCl led to a short-
lasting increase of plasma NT-pro-ANP (prohormone of ANP) and a
delayed increase in plasma NT-pro-BNP, together with a parallel
increase in urine flow, renal excretion of sodium and NT-pro-BNP.
The increased urinary NT-pro-BNP excretion during volume loading
suggests a possible role of BNP in sodium homeostasis in men [44]. In
a study on 74 male subjects aged 50 or older a correlation between
increased NT-pro-BNP and leg edema has been found [45].
Furthermore, BNP is used for volume estimation in dialysis patients,
since BNP level variations correlate positively with volume status
alterations in this specific patient group [46].
NP Pathophysiology
The driving force behind excessive diuresis during night time can
be a rise in nocturnal sodium excretion due to increased ANP levels.
This is known to be the pathophysiological mechanism of nocturnal
polyuria in patients with sleep apnea syndrome [47]. The inspiratory
efforts against a closed airway during sleep apnea cause a negative
intrathoracic pressure with cardiac distension that leads to the release
of ANP with consequential sodium and water excretion and inhibition
of both ADH and the renin-angiotensin-aldosterone system [48].
 
ANP and BNP levels are usually higher in patients with severe heart
failure compared to people with normal heart function, so this is also
assumed to be the mechanism of NP in patients with congestive heart
failure. And although increased ANP levels have been described in the
older population with NP, other studies do not observe significant
differences in natriuretic peptide levels between NP patients and
controls, both without cardiac failure. This suggests that NP might be
a sign of undetected cardiac failure in older persons [49,50].
Therapeutical implications
Furosemide is a short-acting loop diuretic often used in the
treatment of heart failure or edema. When administered in the
afternoon, approximately 6 hours before bedrest, it stimulates an early
evening diuresis resulting in a decreased nocturnal voiding frequency
[38]. This has been demonstrated in older men with lower urinary
tract symptoms (LUTS) and can safely be combined with
desmopressin or terazosin [51,52]. In children with desmopressin-
resistant nocturnal polyuria increased sodium excretion overnight was
found and adding furosemide in the morning to desmopressin
treatment led to an increase of diuresis of diluted urine in the morning
without affecting the concentrating capacity overnight [53]. As in
desmopressin treatment it is important to regularly check electrolyte
balance since furosemide affects not only sodium excretion, but also
enhances potassium, calcium and magnesium excretion (Table1 and
Figure 1).
Antidiuresis Diuresis
What? Arginine-vasopressine or
antidiuretic hormone
Angiotensine II Aldosterone Atrial natriuretic peptie
Site of synthesis? Neurohypophysis Lungs Adrenal glands Atria
Site of effect in kidney? Cortical and medullary collecting
tubule
Proximal tubule Cortical collecting tubule
(epithelial sodium channels)
Glomeruli & inner medullary collecting
duct
Receptors? V2-receptor AT1-receptor MR-receptor NPR-A
Main effect in kidney? Antidiuresis through water
reabsorption by fusion of
aquaporin-2 channels with
luminal membrane
Antidiuresis through:
Sodium reabsorption, both
directly and indirectly
(stimulation of aldosterone
secretion)
Antidiuresis through sodium
reabsorption
Natriuresis through:
inhibition of sodium reabsorption
directly and indirectly (inhibition of
RAAS)
inhibition of water reabsorption
indirectly (diminish response to ADH)
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Water reabsorption, indirectly
(sodium reabsorption and
stimulation of ADH)
Stimulating factors? Hyperosmolality
Hypovolemia
stress e.g. pain
hypoglycemia
Increase in renin due to:
Low blood volume
Low Na+ concentration in
distal tubule
Drop in blood pressure
Ang II
Plasma K+ concentration
ACTH
Volume expansion with atrial stretch
Aldosterone escape
Role in nocturnal polyuria? Reduced e.g. in nocturnal
enuresis
Reduced e.g. in hypertension Reduced e.g. sleep apnea
syndrome
Increased e.g. in heart failure
V: Vasopressin; AT: Angiotensin; MR: Mineralocorticoid; NPR: Natriuretic Peptide Receptor; ADH: Antidiuretic Hormone; RAAS: Renin-Angiotensin-Aldosteron
System; Ang: Angiotensin; ACTH: Adrenocorticotropic Hormone
Table 1: Main antidiuretic and diuretic hormones and characteristics
Figure 1: Stimulating and inhibiting effects of hormones involved
in water and sodium handling and therapeutical implications
Other hormones
Prostaglandins: Prostaglandins are derivatives from the metabolism
of arachidonic acid, catalyzed by the coclooxygenase (COX) enzyme.
In the kidney, COX-1 controls renal hemodynamics and glomerular
filtration rate, COX-2 plays a role in salt and water excretion [54].
Prostaglandin E2 (PGE2) is synthesized both in the glomeruli and
tubules, it lowers the renal vascular resistance and increases renal
perfusion through dilatation of the renal vascular bed. The tubular
effect of PGE2 is an antagonistic effect of ADH and thus implies local
modulation of water and electrolyte transport; however, the major
function of the ADH-prostaglandin relationship may be the regulation
or renal hemodynamics [55]. ProstaglandinI2 (PGI2) or prostacyclin is
synthesized in the glomeruli and mainly affects renal homeostatic
mechanisms by antagonizing the vasoconstrictor effects of both
norepinephrine and angiotensin II in the vessels [54,55]. The effects of
ANP are also influenced by prostaglandins, since the ANP-related
natriuresis seems to depend on redistribution of renal blood flow due
to an increase in urinary excretion of prostaglandins and a decrease of
renin secretion [56].
Since prostaglandins are synthezised through COX-enzymes, a
beneficial effect of non-steroidal anti-inflammatory drugs in some
patients with nocturia is not surprising. A Japanese study in which
men with benign prostate hypertrophy (BPH) were treated with
loxoprofen because BPH treatment did not improve nocturia, reported
in 74% of the cases an improvement or disappearance of nocturia [57].
Treatment of 26 patients with nocturnal polyuria with diclofenac gave
a significant decrease in nocturia episodes from 2.7 to 2.3 and a
significant decrease in ratio of night time to 24h urine volume from
44% to 39%, however, clinical relevance of these decreases is doubtful
[58]. The effect of NSAIDs on nocturia can be explained through
several pathways: reduction of urine production at the kidney,
decrease in urinary sensation at the bladder, increase of urinary
sensation threshold at the central nervous system or alteration of sleep
at the brain. However, PGE2 and PGI2 normally only start playing an
important role in maintaining GFR in patients with compromised
renal hemodynamics. This means that a good effect of NSAIDs is
mainly expected in older patients or patients with congestive heart
failure, cirrhosis or nephrosis, but since there is a risk of gastric ulcers
and deterioration of kidney function, NSAIDs are not indicated to be
used in older or precarious patients. Most common reported adverse
events in treatment with NSAIDs for nocturia are gastric discomfort,
leg edema and urinary frequency in the morning [57,58].
Melatonin: Melatonin is a pineal hormone that is particularly
known for its circadian secretion rhythm with a prominent nocturnal
peak as a response to the light-dark rhythm. It also influences the
circadian rhythm of other hormones and since the melatonin (MT)
receptors are distributed throughout the whole body, it has a large
variation in effects [59]. These effects also imply an influence of the
above mentioned hormones.
A colocalization of melatonin receptors and ADH neurons in the
suprachiasmatic, paraventricular and supraoptic nuclei has been
described, suggesting that melatonin might directly modulate the
hypothalamic-pituitary-adrenal axis and thus might also have an
impact on the antidiuretic effect of ADH [60]. Besides, a renin-
angiotensin system in the brain seems to modulate melatonin
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synthesis. Interaction between locally produced angiotensin II and
melatonin in the pineal gland affects the peripheral renin-angiotensin
system and thus indirectly urine production [5]. The relation between
neuroendocrine functions and the cardiovascular system might also be
regulated through ANP, since acute injections of ANP stimulate
melatonin secretion, however, administration of oral melatonin does
not seem to affect ANP plasma concentrations; the true link between
melatonin and ANP remains to be elucidated [61,62].
Only few studies are performed with melatonin as treatment for
nocturia. One study examined the effect of 2 mg melatonin on
nocturia compared to placebo in patients with benign prostate
hyperplasia. A statistically significant difference in nocturia episodes
was found, however, a reduction of 0.32 episodes does not seem
clinically relevant. Besides, since it was studied in a population with
BPH, it is difficult to estimate the influence of BPH on nocturia and on
the effect of melatonin treatment [63]. Another study comparing the
effect of melatonin and rilmazafone, a hypnotic agent, on nocturia also
showed a significant decrease in nocturia episodes, together with an
increase in the serum melatonin levels. Before treatment, all patients
considered their nocturia problem as bothersome, after 4 weeks of
treatment, 70% of the patients considered it to be no longer
bothersome.
 
Although the link between sleep disorders and nocturia has not been
elucidated yet, it is certain that there is a relation between both and it
is important to counsel about the presence of sleep disturbances when
considering treatment for nocturia.
Sex hormones: In women, estrogens and progestogens are the main
sex hormones. Estrogens are steroid hormones synthesized from
androgens under stimulation of follicle stimulating hormone by the
ovaries and in lower concentrations by the liver, adrenal glands,
breasts and fat. Action of estrogens is mediated by the estrogen
receptor, resulting in various effects on menstrual cycle, sexual
characteristics et cetera [64].
Progesterone is also a steroid hormone synthesized from the
cholesterol-derived pregnenolone by the ovaries and adrenal glands. It
is the precursor of aldosterone and after conversion into 17-
hydroxyprogesterone of cortisol and androstenedione, the latter can be
converted to testosterone, estrone and estradiol. Progesterone binds to
the progesterone receptor and has key effects in the reproductive
system and nervous system [65].
 
Testosterone is in small amounts present in women, but is the main
sex hormone in men. Like the other steroid hormones, it is derived
from cholesterol. Testosterone exerts its effect through binding to the
androgen receptor at one hand and by conversion to estradiol and
activation of estrogen receptors at the other hand. It plays a key role in
the development of male reproductive tissues such as testes and
prostate, it is necessary for normal sperm development and promotes
secondary sexual characteristics. Furthermore, testosterone is essential
for general well-being [66].
ADH secretion is subjected to circadian rhythms, but also to the
menstrual cycle in women. Increased basal and nocturnal ADH
concentrations are found in the midfollicular phase of the menstrual
cycle; postmenopausal women who take in estrogen will have
increased ADH, whereas the combination of estrogen and
progesterone lowers the ADH concentrations [67-69].
High estrogen states decrease baseline plasma-osmolality and
sodium by resetting of the osmoreceptors for thirst and ADH release.
However, in this situation ADH secretion persists and slightly
hypotonic plasma is maintained [67]. Another study suggests that
3beta- 17beta-estradiol (E2) augments osmotic ADH secretion with
water retention as a consequence, however, the enhanced fluid
retention was mainly based on an increase in renal sodium
reabsorption [68].
The effects on sodium excretion can be attributed to the relation
between estrogens and progestogens and the renin-aldosterone
system. High doses of estrogens stimulate the synthesis of
angiotensinogen and the consecutive increase in angiotensin II slightly
reduces renal blood flow and increases sodium and blood pressure. At
the other hand, endogenous or exogenous progesterone promotes
sodium loss which leads to a compensatory increase in the activity of
the renin-angiotensin-aldosterone system. Combination treatment of
ethinylestradiol and progestogens may therefore enhance the estrogen
effects on body sodium and blood pressure, also since some synthetic
progestogens are weak estrogen receptor agonists [6].
Literature on the link between androgens and the hormones
involved in the water and sodium homeostasis is limited. Men seem to
have higher plasma concentrations of ADH compared to women and
present with a higher sensitivity in ADH response [68]. Gender
differences in blood pressure are attributed to the relation between
androgens and the renin-aldosterone system. A greater activation of
the RAS with higher blood pressure levels in males is partly attributed
to these androgens. Castration seems to result in a normalization of
blood pressure and downregulation of the intrarenal RAS [70].
Athough some studies do not report an effect, several other studies
have shown a beneficial effect of estrogen on the symptom of nocturia
[71]. As well oral administration as topical application of estrogen in
postmenopausal women leads to a significant decrease in nocturnal
frequency within 3 months after the beginning of the therapy [72]. A
trial with 2 mg 17 beta-oestradiol combined with 2.5, 5, 10 or 15 mg
dydrogesterone led to complete cure of nocturia in 65% of the 26
postmenopausal women with baseline nocturia who completed 6
months of hormonal therapy [73]. A randomized controlled trial
studying the effect of oestradiol-releasing rings and oestriol pessaries
in postmenopausal women showed a decrease in the number of
nocturia episodes of 51% and 54%, respectively [74]. So regardless of
the type of estrogen replacement therapy that is used, an effect on
nocturia can be seen.
No direct effect of testosterone on nocturia has been described, but
drugs that indirectly target testosterone such as 5-alpha-reductase
inhibitors seem to have an effect on nocturia, however, the effect is
rather small. Doxazosin and combination therapy with finasteride
resulted in a larger reduction of nocturia-episodes than placebo, but
the net difference was less than 0.20 fewer nocturnal voiding episodes
at 1 and 4 years [75] (Table 2).
Hormones Main effect Consequence Therapeuticalimplication for NP
Prostaglandins:
PGE2
PGI2
? antagonizes ADH
? antagonizes RAAS Diuresis NSAIDs
Melatonin stimulates ADHstimulates RAAS Antidiuresis Melatonin
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Sex hormones:
estrogens
progesterone
testosterone
? stimulates ADH,
Renin, Ang II, ANP;
inhibits Aldosteron
? stimulates Aldosteron;
antagonizes ADH, ANP
? stimulates ADH,
Renin, Ang II
Antidiuresis
Replacement
therapy if
necessary
PGE2: Prostaglandin E2; PGI2: Prostaglandin I2; ADH: Antidiuretic Hormone;
RAAS: Renin-Angiotensin-Aldosterone System; ANP: Atrial Natriuretic Peptide;
NSAIDs: Non-Steroidal Anti-Inflammatory Drugs
Table 2: Influence of prostaglandins, melatonin and sex hormones on
the antidiuretic and diuretic hormones
Conclusion
Different hormonal pathways are involved in urine production.
With increasing age circadian rhythms of these hormones vanish,
making older people more susceptible to a large nocturnal urine
production. However, at any age, it is an imbalance in this hormonal
regulation that can lead to an excessive urine production and thus
nocturnal polyuria.
 
Addressing the underlying pathologies that affect either directly or
indirectly water or sodium handling and thus urine production can
relieve people from bothersome nocturia or nocturnal urinary
incontinence based on nocturnal polyuria and can improve both their
sleep quality and quality of life.
References
1. Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, et al.
(2012) A contemporary assessment of nocturia: definition, epidemiology,
pathophysiology, and management--a systematic review and meta-
analysis. Eur Urol 62: 877-890.
2. Herek J, Fitzgerald M, Mohindra M, Wickman C, Leehey J, et al (2010)
Solute and Water Excretion Patterns in Patients with Nocturnal Polyuria.
International Journal of Nephro-Urology 2: 526-531.
3. Miller M (2000) Nocturnal polyuria in older people: pathophysiology and
clinical implications. J Am Geriatr Soc 48: 1321-1329.
4. Carey RM, Siragy HM (2003) Newly recognized components of the
renin-angiotensin system: Potential roles in cardiovascular and renal
regulation. Endocrine Reviews 24: 261-271.
5. Campos LA, Cipolla-Neto J, Amaral FG, Michelini LC, Bader M, et al.
(2013) The Angiotensin-melatonin axis. Int J Hypertens 2013: 521783.
6. Oelkers WK (1996) Effects of estrogens and progestogens on the renin-
aldosterone system and blood pressure. Steroids 61: 166-171.
7. Zimmerman EA, Nilaver G, Hou-Yu A, Silverman AJ (1984)
Vasopressinergic and oxytocinergic pathways in the central nervous
system. Fed Proc 43: 91-96.
8. Sladek CD (1983) Regulation of vasopressin release by neurotransmitters,
neuropeptides and osmotic stimuli. Prog Brain Res 60: 71-90.
9. Robertson GL, Athar S (1976) The interaction of blood osmolality and
blood volume in regulating plasma vasopressin in man. J Clin Endocrinol
Metab 42: 613-620.
10. Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab
11: 406-410.
11. Lencer WI, Brown D, Ausiello DA, Verkman AS (1990) Endocytosis of
water channels in rat kidney: cell specificity and correlation with in vivo
antidiuresis. Am J Physiol 259: C920-932.
12. Field MJ, Stanton BA, Giebisch GH (1984) Influence of ADH on renal
potassium handling: a micropuncture and microperfusion study. Kidney
Int 25: 502-511.
13. Asplund R (2002) Diuresis pattern, plasma vasopressin and blood
pressure in healthy elderly persons with nocturia and nocturnal polyuria.
Neth J Med 60: 276-280.
14. Moon DG, Jin MH, Lee JG, Kim JJ, Kim MG, et al. (2004) Antidiuretic
hormone in elderly male patients with severe nocturia: a circadian study.
BJU Int 94: 571-575.
15. AbdelFatah D, Shaker H, Ismail M, Ezzat M (2009) Nocturnal polyuria
and nocturnal arginine vasopressin (AVP): a key factor in the
pathophysiology of monosymptomatic nocturnal enuresis. Neurourol
Urodyn 28: 506-509.
16. Akiyama T, Hirayama A, Fujimoto K, Torimoto K, Yoshida K, et al.
(2007) Cutoff value of urinary arginine vasopressin for nocturnal
polyuria in elderly men. Urology 69: 98-102.
17. Hirayama A, Fujimoto K, Akiyama T, Hirao Y (2006) Decrease in
nocturnal urinary levels of arginine vasopressin in patients with
nocturnal polyuria. Urology 68: 19-23.
18. CvetkoviÄ RS, Plosker GL (2005) Desmopressin: in adults with nocturia.
Drugs 65: 99-107.
19. Chang YL, Lin AT, Chen KK (2007) Short-term effects of desmopressin
on water and electrolyte excretion in adults with nocturnal polyuria. J
Urol 177: 2227-2229.
20. Juul KV, Klein BM, Nørgaard JP (2013) Long-term durability of the
response to desmopressin in female and male nocturia patients.
Neurourol Urodyn 32: 363-370.
21. Juul KV, Klein BM, Sandström R, Erichsen L, Nørgaard JP (2011) Gender
difference in antidiuretic response to desmopressin. Am J Physiol Renal
Physiol 300: F1116-1122.
22. Griendling KK, Murphy TJ, Alexander RW (1993) Molecular biology of
the renin-angiotensin system. Circulation 87: 1816-1828.
23. Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-
angiotensin systems. Physiol Rev 86: 747-803.
24. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ (1981)
Maintenance of blood pressure by the renin-angiotensin system in
normal man. Nature 291: 329-331.
25. Kurtz A (2011) Renin release: sites, mechanisms, and control. Annu Rev
Physiol 73: 377-399.
26. Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, et al. (2013)
Regulation of renin secretion by renal juxtaglomerular cells. Pflugers
Arch 465: 25-37.
27. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, et al.
(2005) Distinct roles for the kidney and systemic tissues in blood
pressure regulation by the renin-angiotensin system. J Clin Invest 115:
1092-1099.
28. Funder JW, Mihailidou AS (2009) Aldosterone and mineralocorticoid
receptors: Clinical studies and basic biology. Mol Cell Endocrinol 301:
2-6.
29. Granger JP, Burnett JC Jr, Romero JC, Opgenorth TJ, Salazar J, et al.
(1987) Elevated levels of atrial natriuretic peptide during aldosterone
escape. Am J Physiol 252: R878-882.
30. Rittig S, Matthiesen TB, Pedersen EB, Djurhuus JC (2006) Circadian
variation of angiotensin II and aldosterone in nocturnal enuresis:
relationship to arterial blood pressure and urine output. J Urol 176:
774-780.
31. Matthiesen TB, Rittig S, Nørgaard JP, Pedersen EB, Djurhuus JC (1996)
Nocturnal polyuria and natriuresis in male patients with nocturia and
lower urinary tract symptoms. J Urol 156: 1292-1299.
32. Feldstein CA (2013) Nocturia in arterial hypertension: a prevalent,
underreported, and sometimes underestimated association. J Am Soc
Hypertens 7: 75-84.
33. Satoh M, Kikuya M, Ohkubo T, Mori T, Metoki H, et al. (2011)
Aldosterone-to-renin ratio and nocturnal blood pressure decline in a
general population: the Ohasama study. J Hypertens 29: 1940-1947.
34. Pelayo JC, Harris DC, Shanley PF, Miller GJ, Schrier RW (1988)
Glomerular hemodynamic adaptations in remnant nephrons: effects of
verapamil. Am J Physiol 254: F425-431.
Citation: Goessaert A, Walle JV, Kapila A, Everaert K (2014) Hormones and Nocturia: Guidelines for Medical Treatment?. J Steroids Hormon Sci
5: 130. doi:10.4172/2157-7536.1000130
Page 6 of 7
J Steroids Hormon Sci
ISSN:2157-7536 JSHS an open access journal Volume 5 • Issue 2 • 1000130
35. Weinberger MH (1996) Salt sensitivity of blood pressure in humans.
Hypertension 27: 481-490.
36. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, et al. (1997) Sodium
restriction shifts circadian rhythm of blood pressure from nondipper to
dipper in essential hypertension. Circulation 96: 1859-1862.
37. Fukuda M, Wakamatsu-Yamanaka T, Mizuno M, Miura T, Tomonari T,
et al.( 2011) Angiotensin receptor blockers shift the circadian rhythm of
blood pressure by suppressing tubular sodium reabsorption. Am J
Physiol Renal Physiol 301:953-957.
38. Reynard JM, Cannon A, Yang Q, Abrams P (1998) A novel therapy for
nocturnal polyuria: a double-blind randomized trial of frusemide against
placebo. Br J Urol 81: 215-218.
39. Cho Y, Somer BG, Amatya A (1999) Natriuretic peptides and their
therapeutic potential. Heart Dis 1: 305-328.
40. Chopra S, Cherian D, Verghese PP, Jacob JJ (2013) Physiology and
clinical significance of natriuretic hormones. Indian J Endocrinol Metab
17: 83-90.
41. Ganguly A (1992) Atrial natriuretic peptide-induced inhibition of
aldosterone secretion: a quest for mediator(s) Am J Physiol 263:
E181-194.
42. Nonoguchi H, Sands JM, Knepper MA (1988) Atrial Natriuretic Factor
Inhibits Vasopressin-Stimulated Osmotic Water Permeability in Rat
Inner Medullary Collecting Duct. J Clin Invest 82:1383-1390.
43. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, et al. (1991) Brain
Natriuretic Peptide As A Novel Cardiac Hormone in Humans - Evidence
for An Exquisite Dual Natriuretic Peptide System, Atrial-Natriuretic-
Peptide and Brain Natriuretic Peptide. J Clin Invest 87:1402-1412.
44. Heringlake M, Heide C, Bahlmann L, Eichler W, Pagel H, et al. (2004)
Effects of tilting and volume loading on plasma levels and urinary
excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers.
J Appl Physiol (1985) 97:173-179.
45. Hirayama A, Torimoto K, Yamada A, Tanaka N, Fujimoto K, et al.
(2011) Relationship between nocturnal urine volume, leg edema, and
urinary antidiuretic hormone in older men. Urology 77: 1426-1431.
46. Roueff S, Martin E, Chauffert ML, Poli I, Kihal K, et al. (2008) Brain
natriuretic peptide variations are linked to volume status in hemodialysis
patients. Clin Nephrol 70: 508-513.
47. Bing MH, Jennum P, Moller LA, Mortensen S, Lose G (2012) Obstructive
sleep apnea in a Danish population of men and women aged 60-80 years
with nocturia. J Clin Sleep Med 8: 515-520.
48. Umlauf MG, Chasens ER (2003) Sleep disordered breathing and
nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 7: 403-411.
49. Carter PG, Cannon A, McConnell AA, Abrams P (1999) Role of atrial
natriuretic peptide in nocturnal polyuria in elderly males. Eur Urol 36:
213-220.
50. Torimoto K, Hirayama A, Samma S, Yoshida K, Fujimoto K, et al. (2009)
The relationship between nocturnal polyuria and the distribution of body
fluid: assessment by bioelectric impedance analysis. J Urol 181: 219-224.
51. Cho MC, Ku JH, Paick JS (2009) Alpha-Blocker Plus Diuretic
Combination Therapy as Second-line Treatment for Nocturia in Men
With LUTS: A Pilot Study. Urology 73:549-553.
52. Fu FG, Lavery HJ, Wu DL (2011) Reducing nocturia in the elderly: a
randomized placebo-controlled trial of staggered furosemide and
desmopressin. Neurourol Urodyn 30: 312-316.
53. De Guchtenaere A, Vande Walle C, Van Sintjan P, Donckerwolcke R,
Raes A, et al. (2007) Desmopressin resistant nocturnal polyuria may
benefit from furosemide therapy administered in the morning. J Urol
178: 2635-2639.
54. Weir MR (2002) Renal effects of nonselective NSAIDs and coxibs. Cleve
Clin J Med 69 Suppl 1: SI53-58.
55. Schlondorff D (1986) Renal prostaglandin synthesis. Sites of production
and specific actions of prostaglandins. Am J Med 81: 1-11.
56. Salazar FJ, Bolterman R, Hernandez I, Quesada T, Romero JC (1987)
Role of prostaglandin and angiotensin II in ANP-induced natriuresis.
Agents Actions Suppl 22: 111-123.
57. Araki T, Yokoyama T, Kumon H (2004) Effectiveness of a nonsteroidal
anti-inflammatory drug for nocturia on patients with benign prostatic
hyperplasia: a prospective non-randomized study of loxoprofen sodium
60 mg once daily before sleeping. Acta Med Okayama 58: 45-49.
58. Addla SK, Adeyoju AB, Neilson D, O'Reilly P(2006) Diclofenac for
treatment of nocturia caused by nocturnal polyuria: A prospective,
randomised, double-blind, placebo-controlled crossover study. European
Urology 49:720-725.
59. Hardeland R (2012) Neurobiology, pathophysiology, and treatment of
melatonin deficiency and dysfunction. ScientificWorldJournal 2012:
640389.
60. Wu YH, Zhou JN, Balesar R, Unmehopa U, Bao AM, et al. (2006)
Distribution of MT1 melatonin receptor immunoreactivity in the human
hypothalamus and pituitary gland: Colocalization of MT1 with
vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp
Neurol 499: 897-910.
61. Lissoni P, Pelizzoni F, Perego M, Fondrini G, Grugni G, et al. (1990) A
study of heart-pineal interactions: atrial natriuretic peptide response to
melatonin administration in healthy humans. J Pineal Res 9: 167-170.
62. Lissoni P, Pelizzoni F, Grugni G, Guzzaloni G, Mauri O, et al. (1990)
Melatonin Response to Atrial-Natriuretic-Peptide Administration in
Healthy-Volunteers. J Cardiovasc Pharmacol 16:850-852.
63. Drake MJ, Mills IW, Noble JG (2004) Melatonin pharmacotherapy for
nocturia in men with benign prostatic enlargement. J Urol 171:
1199-1202.
64. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Production
and actions of estrogens. N Engl J Med 346: 340-352.
65. Graham JD, Clarke CL (1997) Physiological action of progesterone in
target tissues. Endocr Rev 18: 502-519.
66. Shahidi NT (2001) A review of the chemistry, biological action, and
clinical applications of anabolic-androgenic steroids. Clin Ther 23:
1355-1390.
67. Graugaard-Jensen C, Hvistendahl GM, Frøkiaer J, Bie P, Djurhuus JC
(2008) The influence of high and low levels of estrogen on diurnal urine
regulation in young women. BMC Urol 8: 16.
68. Stachenfeld NS, DiPietro L, Palter SF, Nadel ER (1998) Estrogen
influences osmotic secretion of AVP and body water balance in
postmenopausal women. Am J Physiol 274:187-195.
69. Vokes TJ, Weiss NM, Schreiber J, Gaskill MB, Robertson GL (1988)
Osmoregulation of thirst and vasopressin during normal menstrual cycle.
Am J Physiol 254: R641-647.
70. Maric-Bilkan C, Manigrasso MB (2012) Sex differences in hypertension:
contribution of the renin-angiotensin system. Gend Med 9: 287-291.
71. Moehrer B, Hextall A, Jackson S (2003). Oestrogens for urinary
incontinence in women. Cochrane Database Syst Rev 2: CD001405.
72. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, et al. (2006) A
randomized comparative study of the effects of oral and topical estrogen
therapy on the lower urinary tract of hysterectomized postmenopausal
women. Fertil Steril 85: 155-160.
73. Kok AL, Burger CW, van de Weijer PH, Voetberg GA, Peters-Muller ER,
et al. (1999) Micturition complaints in postmenopausal women treated
with continuously combined hormone replacement therapy: a
prospective study. Maturitas 31: 143-149.
74. Lose G, Englev E (2000) Oestradiol-releasing vaginal ring versus oestriol
vaginal pessaries in the treatment of bothersome lower urinary tract
symptoms. BJOG 107: 1029-1034.
75. Johnson TM 2nd, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, et al.
(2007) The effect of doxazosin, finasteride and combination therapy on
nocturia in men with benign prostatic hyperplasia. J Urol 178: 2045-2050.
 
Citation: Goessaert A, Walle JV, Kapila A, Everaert K (2014) Hormones and Nocturia: Guidelines for Medical Treatment?. J Steroids Hormon Sci
5: 130. doi:10.4172/2157-7536.1000130
Page 7 of 7
J Steroids Hormon Sci
ISSN:2157-7536 JSHS an open access journal Volume 5 • Issue 2 • 1000130
